Thursday, July 11, 2019 - 16:00 to 17:00
MSI Small Lecture Theatre
Mr. William Farnaby
Dr Joachim Broeker
Joachim did his MSc (2000) and PhD (2004) at the Vienna University of Technology under the supervision of Peter Gaertner, working on chiral linkers and their application as auxiliaries for stereoselective synthesis on solid phase. In 2004 he joined the Boehriner-Ingelheim oncology site in Vienna working in Medicinal Chemistry first as a postdoc and then as a scientist mainly on kinase projects in the lab of Heinz Stadtmueller. After staying at the BI virology research site in Laval, Canada as a visiting scientist in 2009, he was promoted to research lab head in 2012, and since then has worked on early and late stage projects in the field of deubiquitinases and epigenetics and recently in the MDM2 and KRAS programs.
Protein protein interactions (PPIs) are the basis of many important cellular processes, therefore PPI interfaces represent a highly promising although challenging class of targets for the development of cancer therapeutics. Despite the difficulties associated with targeting PPIs, important progress has been made in the last years with fragment based drug discovery (FBDD) playing a pivotal role in improving their tractability. In this talk the application of FBDD in targeting MDM2::p53 and KRAS::CRAF, 2 examples of PPI targets in the cancer research portfolio of Boehringer Ingelheim, will be presented.